It remains to be seen if Vamorolone may replace glucocorticoids and/or MR antagonists in the clinic, but it has already demonstrated efficacy in preclinical studies using dystrophic mice and is currently being tested in DMD patient trials [125,161,162]. The gene discussed is NR3C2; the disease is Duchenne muscular dystrophy.